Skip to content

Clinical trials

Completed Observational HIV Infections trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: HIV Infections Phase: Observational Status: Completed Clear all

611 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200011
200112
200221
200322
200429
200533
200632
200739
200839
200951
201033
201116
201213
20138
20144
201512
20167
201717
201825
201916
20209
202118
202216
202311
20247
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed611

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)127
University of North Carolina, Chapel Hill26
National Cancer Institute (NCI)21
Boehringer Ingelheim16
ANRS, Emerging Infectious Diseases11
National Heart, Lung, and Blood Institute (NHLBI)11
ViiV Healthcare9
AIDS Malignancy Consortium8
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections8
Thai Red Cross AIDS Research Centre8

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
HIV Infections611
Acquired Immunodeficiency Syndrome116
Hepatitis C27
Sexually Transmitted Diseases17
HIV Seropositivity15
Hepatitis B15
Tuberculosis15
Cardiovascular Diseases13
Substance-Related Disorders12
Neoplasms11

Trials

Showing 1 to 25 of 611. Each trial links to its page on Pharma Observatory.

511 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.